The combination of αmPD-1 mAb with ROR1 DAC enhanced the suppression of tumor growth compared to ROR1 DAC monotherapy, consistent with studies of JQ1 and PD-1 mAb combinations in non-small cell lung cancer 47. Here, PDCD1 is linked to non-small cell lung carcinoma.